Equity Overview
Price & Market Data
Price: $0.526
Daily Change: -$0.054 / 10.27%
Daily Range: $0.52 - $0.592
Market Cap: $1,121,081
Daily Volume: 770,242
Performance Metrics
1 Week: -32.68%
1 Month: -33.29%
3 Months: -27.99%
6 Months: -75.26%
1 Year: -75.94%
YTD: -71.36%
Company Details
Employees: 2
Sector: Health technology
Industry: Biotechnology
Country:
Details
Salarius Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is based in Houston, Texas.